10-Q: Aprea Therapeutics Reports Q1 2026 Financials, Advances Pipeline

Aprea Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing financial results, ongoing clinical trials for APR-1051 and ATRN-119, and strategic updates.

Summary

• Aprea Therapeutics, Inc. reported a net loss of $3.3 million for the first quarter of 2026, compared to a net loss of $3.9 million in the same period of 2025.
• Research and development expenses decreased to $1.6 million from $2.5 million year-over-year, primarily due to reduced spending on the ATRN-119 clinical trial.
• The company ended the quarter with $46.5 million in cash and cash equivalents, which it expects to fund operations into the first quarter of 2028.
• Significant capital raises occurred through private placements in December 2025, January 2026, and March 2026, totaling approximately $30 million in upfront gross proceeds from the March 2026 placement alone.
• Clinical development continues for APR-1051, with preliminary results showing a dose-response trend and partial responses in patients with PPP2R1A-mutated uterine serous carcinoma.
• The company is exploring combination approaches for ATRN-119 and initiating IND-enabling studies for APR-1602 in late 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as cautiously negative due to continued net losses and operational challenges, despite positive clinical data and successful capital raises.

Positives

• The company's cash position of $46.5 million provides runway into Q1 2028, indicating sufficient funding for ongoing operations.
• Successful capital raises through multiple private placements in late 2025 and early 2026 have bolstered the company's financial resources.
• Preliminary clinical data for APR-1051 shows early signs of anti-tumor activity, including partial responses in specific patient populations.
• Research and development expenses have decreased year-over-year, suggesting improved cost management or a shift in development focus.
• The company is actively exploring new development opportunities for ATRN-119 through combination approaches.

Negatives

• The company continues to incur significant net losses ($3.3 million in Q1 2026) and has an accumulated deficit of $336.9 million.
• Grant revenue has ceased, with the prior grant from the National Cancer Institute of the National Institutes of Health (NIH) being exhausted.
• The company has paused further patient enrollment in certain arms of the ABOYA-119 Phase I study for ATRN-119 as it explores combination approaches.
• The company is still in the early stages of clinical development for its key product candidates, with no guarantee of future commercial success.
• The company is subject to risks associated with being a smaller reporting company and potential delisting from Nasdaq due to low stock price.

Risks

• The company is substantially dependent on the success of APR-1051 and ATRN-119, and their clinical trials may not be successful.
• The company has limited operating history and has never generated commercial revenue, making future viability uncertain.
• The company will require substantial additional funding, which may not be available on acceptable terms or at all.
• If the company fails to maintain compliance with Nasdaq listing requirements, its common stock could be delisted.
• The results of early-stage clinical trials may not be predictive of future results in later-stage trials.
• The company may face difficulties enrolling patients in clinical trials, which could delay development.
• Adverse side effects or limited efficacy identified during development could lead to the abandonment of product candidates.
• The company relies on third parties for clinical trials and manufacturing, which introduces risks of unsatisfactory performance or delays.
• Intellectual property protection is crucial, and challenges to patents or failure to obtain broad protection could harm the business.
• Regulatory approval processes are lengthy, uncertain, and expensive, with no guarantee of success.
• Changes in government regulations and policies could impact the difficulty and cost of obtaining marketing approval.
• The company's stock price has been and may continue to be volatile.
• The company is subject to risks associated with global economic uncertainty and capital markets disruption.

Future Outlook

The company believes its current cash balance of approximately $46.5 million will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2028. The company expects research and development expenses to continue to increase as it progresses clinical trials for APR-1051 and explores combination approaches for ATRN-119.

Management Comments

• The company is currently dosing patients in the 300mg cohort for APR-1051 and plans to further dose patients at 400mg and 500mg if deemed safe.
• The company is exploring development opportunities for ATRN-119 in potential combination approaches.
• The company expects open-label safety/efficacy data for APR-1051 to be available throughout 2026 and anticipates completing dose-escalation in Q2 2027.
• The company has initiated an orderly wind-down of the ABOYA-119 study as it explores ATRN-119 in potential combination approaches.

Industry Context

StockSavvy.ai notes that Aprea Therapeutics operates in the highly competitive oncology drug development space, focusing on synthetic lethality. The company's progress with APR-1051, showing early clinical activity, is a positive indicator in a field where novel mechanisms are sought. However, the continued net losses and reliance on capital raises are common challenges for clinical-stage biopharmaceutical companies.

Legal Proceedings

• The company was not subject to any material legal proceedings during the three months ended March 31, 2026, or the year ended December 31, 2025, and no material legal proceedings are currently pending or threatened.

Stakeholder Impact

• Shareholders may experience dilution due to ongoing capital raises and potential future equity financings.
• The company's ability to fund operations into Q1 2028 provides some stability for stakeholders.
• The potential delisting from Nasdaq could negatively impact the liquidity and market price of common stock for shareholders.

Next Steps

• Continue dosing patients in the 300mg cohort for APR-1051 and potentially escalate to 400mg and 500mg.
• Expand enrollment in the ACESOT-1051 study to include at least 50 patients with uterine serous carcinoma and patients with cyclin E-overexpressing, platinum-resistant ovarian cancer.
• Explore ATRN-119 development in potential combination approaches with leading academic centers.
• Initiate IND-enabling studies for APR-1602 in the fourth quarter of 2026.

Key Dates

Recommendation

Aprea Therapeutics presents a mixed picture. While clinical progress with APR-1051 is encouraging and recent capital raises provide a runway, the company continues to incur significant losses, faces potential Nasdaq delisting, and has paused development in certain areas. The path to profitability remains long and uncertain, warranting a cautious 'hold' stance until more definitive clinical and financial milestones are achieved.

Keywords

Aprea Therapeutics, Form 10-Q, Clinical Stage, Oncology, Precision Medicine, APR-1051, ATRN-119, WEE1 inhibitor, ATR inhibitor, Synthetic Lethality, Biotechnology, SEC Filing, Financial Results, Clinical Trials